As from October 14th 2011, Cephalon has joined Teva, a leading global pharmaceutical company.
You can find out more about Teva Pharmaceutical industries at www.tevapharm.com
EXPANDING OUR REACH
Healthcare is a key indicator of the state of advancement of a society. With the aim of contributing to overcoming the challenges that healthcare systems face, Cephalon significantly invests in Research and Development activities and drug delivery technologies in order to provide affordable medicines that make a scientific and economic difference.
Finding new therapeutic solutions for unmet medical needs and populations in need inspires us as a company. In the mid-1990’s, Cephalon's arrival in Europe provided patients and healthcare professionals with a breakthrough treatment for excessive daytime sleepiness associated with narcolepsy, which until that time had been inadequately addressed. Now, Cephalon joins Teva, a leading global pharmaceutical company for which Europe is an important pillar and growth driver.
Innovation and services for patients and healthcare professionals are a day-to-day commitment for all our employees (14/10/11)
WE ARE DRIVEN
Our mission is to discover and develop innovative drugs to
improve patients’ lives. We provide a range of speciality
pharmaceuticals to healthcare professionals and patients
in over 100 countries.
Cephalon’s speciality products are part of Teva’s diversified
global portfolio.
|
|
This site complies with the |
Cephalon participated in the 2011 European Multidisciplinary Congress (ECCO/ESMO) which was held in Stockholm from September 23 to 27, 2011. » more
Cephalon participated in the 7th Congress of the European Federation of IASP Chapters (EFIC), which was held in Hamburg, Germany from September 21–24, 2011. » more
Cephalon Germany offices have moved to an “environment friendly building”, located in the centre of Munich...
» more
